OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Average Price Target from Brokerages

OnKure Therapeutics (NASDAQ:OKUR) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $32.33.

OKUR has been the topic of a number of recent research reports. Oppenheimer decreased their target price on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, March 11th. HC Wainwright lowered their price objective on OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Finally, Evercore ISI initiated coverage on shares of OnKure Therapeutics in a report on Wednesday. They issued an “outperform” rating for the company.

OnKure Therapeutics Stock Performance

Shares of OKUR stock opened at $2.50 on Wednesday. The stock has a market capitalization of $33.59 million, a P/E ratio of -0.20 and a beta of 0.35. The firm’s 50 day moving average is $3.88 and its 200 day moving average is $8.51. OnKure Therapeutics has a 12-month low of $2.42 and a 12-month high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last posted its earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). As a group, equities analysts predict that OnKure Therapeutics will post -4.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OKUR. Aisling Capital Management LP purchased a new stake in OnKure Therapeutics in the 4th quarter worth $762,000. Highbridge Capital Management LLC purchased a new position in OnKure Therapeutics during the 4th quarter valued at $3,438,000. Geode Capital Management LLC purchased a new stake in OnKure Therapeutics in the 4th quarter valued at about $659,000. XTX Topco Ltd purchased a new position in OnKure Therapeutics during the 4th quarter worth $160,000. Finally, Carlyle Group Inc. purchased a new position in shares of OnKure Therapeutics during the fourth quarter valued at $2,326,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.